Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations (original) (raw)
Figure 3
Tumor Nmut and clinical treatment outcome in ovarian cancer patients carrying BRCA germline mutations with LOH at the BRCA loci in tumors.
A) Kaplan-Meier analysis compared PFS and B) OS between Nmut high and low ovarian cancers, all of which carried either a BRCA1 or BRCA2 germline mutation with LOH at the corresponding BRCA locus. C - F) Analysis in individual BRCA1 and BRCA2 mutation carrier groups. C) Kaplan-Meier analysis in patients with _BRCA1_-associated tumors comparing PFS, and D) OS. E) Kaplan-Meier analysis in patients with _BRCA2_-associated tumors comparing PFS, and F) OS. Nmut high and low are defined as a value above or below median Nmut of all mBRCA-associated tumors. Numbers of patients at risk at each interval are given below the graphs. _P_-values are calculated by log-rank test.